Creating new treatments for asthma
Official title: Development of Novel Immunoregulatory Therapeutics for Asthma
Funded at Biotherapeutics, INC. · NIH-10822467 · Data updated 2026-11-12
This study is exploring new ways to treat asthma by using a special approach that helps calm down the immune system, especially for people who haven't found relief with current treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project start | September 20, 2024 |
| Project end | March 14, 2026 |
| Funding year | 2024 |
| Award (this year) | $355,935 |
| NIH project number | 1R43HL172516-01 |
| Project ID | NIH-10822467 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from asthma, particularly those with type 2 asthma or those who have not responded adequately to existing treatments.
✕Less likely to help
Patients with asthma who respond well to current therapies or those with non-allergic asthma may not benefit from this research.
What this research studies
This research focuses on developing innovative therapies for asthma by targeting a new immunoregulatory pathway in immune and epithelial cells. The approach combines advanced computational modeling with experimental methods to create precision immunology products. The goal is to provide a more effective treatment option for patients, particularly those who do not respond well to current therapies. By manipulating regulatory T cells, the research aims to suppress inflammation associated with asthma and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective asthma treatments that significantly improve the quality of life for patients.
How similar studies have gone: While there have been unsuccessful attempts to target similar pathways in asthma treatment, the innovative approach of this research may offer new insights and potential breakthroughs.
Where this research is happening
-
Biotherapeutics, INC.
Blacksburg, United States Active
Researchers
- Principal investigator: Bassaganya-Riera, Josep — Biotherapeutics, INC.
- Study coordinator: Bassaganya-Riera, Josep
Related research
Other NIH-funded projects on the same topics.
-
GLP-1 receptor agonists as immune targets to treat asthma in lean and obese adults
Aims to understand how GLP-1R‑agonist diabetes medicines may directly calm immune cells to reduce asthma in adults who are lean or obese.
-
Understanding how a type of immune cell called ILC2s affect asthma in adults
This grant studies how group 2 innate lymphoid cells influence asthma in adults to help identify new ways to manage airway inflammation.
-
Expanding understanding of asthma in kids through airways and blood profiling
A study at UC San Francisco will profile blood and nasal/sputum samples from 300 youth (including 200 with asthma) over a year to understand how environmental and social factors influence asthma in marginalized communities.
-
Preventing and improving asthma care for children in urban communities
This program will try several approaches — from giving helpful bacteria to babies to allergy immunotherapy and advanced airway testing — to prevent and better treat asthma in children who live in cities.
-
IDEAL project helps predict vaccine response, infections, and asthma in early childhood
A Child-focused program will collect and share saliva, blood, and tissue samples from diverse infants to find biological patterns that predict how vaccines work, how respiratory infections occur, and who develops asthma.
-
Understanding how early-life immune development affects vaccine responses and asthma risk in children
This project uses lab-grown human immune cells from infants and young children to explore why some kids respond poorly to vaccines and are more prone to respiratory infections and asthma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.